SOURCE: IO News Wire

IO News Wire

January 06, 2010 09:00 ET

(OTC: KKUR) Mayo Clinic Research Proves and Confirms ChromoCure's Technology

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - January 6, 2010) - ChromoCure, Inc. (PINKSHEETS: KKUR) announced yesterday the foremost not-for-profit medical group, Mayo Clinic, has proven the chromosomal basis of cancer. By proving the 'aneuploidy theory' of cancer, ChromoCure's chromosome-based cancer-aneuploidy detection technology was affirmed by this research.

ChromoCure's proprietary technology detects the unique chromosomal characteristic found in cancer at all stages. ChromoCure's detection technology is based on the chromosomal theory of cancer, a theory recently proven in the Mayo Clinic research as correct. The Mayo Clinic's research proving the chromosomal basis of cancer was published in the medical journal Cancer Cell.

The Mayo Clinic proving the chromosomal theory of cancer provides further scientific and industry certainty for technology designed around the chromosomal theory of cancer and will help boost the ability for ChromoCure to place its CS200 Chromosomal Scanner in pathology and cancer research labs around the world. The company believes its high-throughput, automated chromosomal scanner to be the first of its type. The company believes its chromosomal scan will become the gold standard of cancer detection and progression measurement worldwide.

Other active stocks are Cord Blood America (OTCBB: CBAI), Millipore Corp (NYSE: MIL), Techne Corp (NASDAQ: TECH)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information